NEW BRUNSWICK (dpa-AFX) - Amgen (AMGN) said that the U.S. Food and Drug Administration has approved the expansion of the Kyprolis or carfilzomib U.S. prescribing information to include its use
The US Food and Drug Administration this week approved daratumumab + hyaluronidase-fihj and carfilzomib plus dexamethasone – a combination that features quickly administered subcutaneous daratumumab.